Item


Degradation of the anticancer drug erlotinib during water chlorination: Non-targeted approach for the identification of transformation products

Erlotinib is a highly potent tyrosine kinase inhibitor used in the treatment of the most common type of lung cancer. Due to its recent introduction, very scarce information is available on its occurrence, environmental fate and toxicological effects on aquatic organisms. During chlorination processes normally carried out in wastewater treatment plants and in the pretreatment of hospital effluents, chlorinated transformation products can be formed with an enhanced toxicity relative to the parent compound.Thus, the reactivity of the cytostatic drug erlotinib in free chlorine-containing water was investigated for the first time in the present work. A non-targeted screening approach based on the use of differential profiling tools was applied in order to reveal its potential transformation products. Structural elucidation of the detected transformation products was performed by ultra-performance liquid chromatography coupled to high-resolution hybrid quadrupole-Orbitrap tandem mass spectrometry. The proposed approach allowed detecting a total of nineteen transformation products, being eighteen of them described for the first time in this work, which demonstrates its potential in environmental analysis. Among them, six compounds presented chlorine atoms in their structures, which may be of major concern. Other transformation products involved hydroxylation and oxidation reactions. Time-course profiles of erlotinib and its transformation products were followed in real wastewater samples under conditions that simulate wastewater disinfection. Although the structures of these transformation products could not be positively confirmed due to lack of standards, their chemical formulas and product ions can be added to databases, which will allow their screening in future monitoring studies

This study has been financially supported by the EU through the FP7 projects CYTOTHREAT (265264) and SOLUTIONS (603437), by the Spanish Ministry of Economy and Competitiveness through the project SCARCE (Consolider-Ingenio 2010 CSD2009-00065), and by the Generalitat de Catalunya (Consolidated Research Groups “2014 SGR 418dWater and Soil Quality Unit” and 2014 SGR 291dICRA

© Water Research, 2015, vol. 85, p. 103-113

Elsevier

Author: Negreira, Noelia
Regueiro, Jorge
López de Alda, Miren
Barceló i Cullerés, Damià
Date: 2015 August 6
Abstract: Erlotinib is a highly potent tyrosine kinase inhibitor used in the treatment of the most common type of lung cancer. Due to its recent introduction, very scarce information is available on its occurrence, environmental fate and toxicological effects on aquatic organisms. During chlorination processes normally carried out in wastewater treatment plants and in the pretreatment of hospital effluents, chlorinated transformation products can be formed with an enhanced toxicity relative to the parent compound.Thus, the reactivity of the cytostatic drug erlotinib in free chlorine-containing water was investigated for the first time in the present work. A non-targeted screening approach based on the use of differential profiling tools was applied in order to reveal its potential transformation products. Structural elucidation of the detected transformation products was performed by ultra-performance liquid chromatography coupled to high-resolution hybrid quadrupole-Orbitrap tandem mass spectrometry. The proposed approach allowed detecting a total of nineteen transformation products, being eighteen of them described for the first time in this work, which demonstrates its potential in environmental analysis. Among them, six compounds presented chlorine atoms in their structures, which may be of major concern. Other transformation products involved hydroxylation and oxidation reactions. Time-course profiles of erlotinib and its transformation products were followed in real wastewater samples under conditions that simulate wastewater disinfection. Although the structures of these transformation products could not be positively confirmed due to lack of standards, their chemical formulas and product ions can be added to databases, which will allow their screening in future monitoring studies
This study has been financially supported by the EU through the FP7 projects CYTOTHREAT (265264) and SOLUTIONS (603437), by the Spanish Ministry of Economy and Competitiveness through the project SCARCE (Consolider-Ingenio 2010 CSD2009-00065), and by the Generalitat de Catalunya (Consolidated Research Groups “2014 SGR 418dWater and Soil Quality Unit” and 2014 SGR 291dICRA
Format: application/pdf
ISSN: 0043-1354 (versió paper)
1879-2448 (versió electrònica)
Document access: http://hdl.handle.net/10256/12574
Language: eng
Publisher: Elsevier
Collection: MICINN/PN 2009-2014/CSD2009-00065
Reproducció digital del document publicat a: http://dx.doi.org/10.1016/j.watres.2015.08.005
Articles publicats (ICRA)
Is part of: © Water Research, 2015, vol. 85, p. 103-113
Rights: Tots els drets reservats
Subject: Aigua -- Contaminació
Water -- Pollution
Contaminants emergents en l’aigua
Emerging contaminants in water
Title: Degradation of the anticancer drug erlotinib during water chlorination: Non-targeted approach for the identification of transformation products
Type: info:eu-repo/semantics/article
Repository: DUGiDocs

Subjects

Authors